Autoimmune thrombocytopenic purpura

Area of Science:

• Hematology
• Immunology
• Internal Medicine

Background:

• Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by low platelet counts.
• Current primary treatments include corticosteroids and splenectomy, which are effective for many patients.

Purpose of the Study:

• To review the efficacy of established and alternative therapies for immune thrombocytopenia (ITP).
• To identify treatment options for patients with ITP who require urgent platelet count elevation or do not respond to standard treatments.

Main Methods:

• Literature review of established and emerging ITP treatment modalities.
• Analysis of therapeutic outcomes based on patient demographics (pediatric vs. adult) and disease severity (acute vs. persistent).

Main Results:

• Corticosteroids and splenectomy are effective for the majority of ITP patients.
• Intravenous immunoglobulin (IVGG) combined with corticosteroids provides rapid platelet increase in acute ITP, especially in children.
• IVGG maintenance therapy can help avoid splenectomy in children with persistent ITP.
• For adults, steroids followed by splenectomy are common; alternative therapies like danazol, vinca alkaloids, cyclophosphamide, and IVGG are considered for refractory cases.

Conclusions:

• Standard therapies (corticosteroids, splenectomy) are effective for most ITP cases.
• IVGG is a valuable option for urgent treatment and maintenance, particularly in pediatric ITP and for adults refractory to splenectomy.
• Further research is needed to fully establish the role of newer therapies like staph protein A pheresis and intravenous anti-D.